Corcept Therapeutics has received a complete response letter from the FDA for its new drug application for relacorilant, a treatment for hypertension caused by hypercortisolism. In the Dec. 31 letter, the FDA acknowledged that Corcept’s GRACE trial met its primary…
Pharmacy
Axsome Therapeutics received FDA acceptance and priority review designation for its supplemental new drug application for AXS-05, a treatment for agitation associated with Alzheimer’s disease. The FDA set a Prescription Drug User Fee Act action date of April 30, 2026.…
The following hospitals and health systems have recently posted job listings for pharmacy leaders. Note: This is not an exhaustive list. Listings were compiled from job-seeker websites.
Vanda Pharmaceuticals has received FDA approval for Nereus (tradipitant), an oral NK-1 receptor antagonist developed to prevent motion-induced vomiting. The approval makes Nereus the first new pharmacologic treatment for motion sickness in more than four decades. Its efficacy is supported…
The FDA said Walgreens has addressed violations related to drug listing deficiencies for one of its products, according to a Dec. 19 close-out letter. The agency previously cited Walgreens in September 2023 for discrepancies in the electronic listing file of…
Advertisement
Mark Cuban, co-founder of Cost Plus Drugs Co., and Optum CEO Patrick Conway, MD, sparred over drug prices, pharmacy benefit managers and a range of other healthcare issues during a Dec. 16 conversation in Washington, D.C. hosted by Johns Hopkins…
Specialty medications, which can cost between $10,000 and upward of $5 million, now account for 52% of U.S. pharmaceutical sales, according to a Dec. 30 report from the Healthcare Distribution Alliance, which represents pharmaceutical distributors. These therapies pose significant logistics…
Duarte, Calif.-based City of Hope and Eli Lilly have partnered on an oncology-based pharmacy residency program. Wafa Samara, PharmD, vice president and chief pharmacy officer at City of Hope, shared news of the partnership in a Dec. 29 LinkedIn post. …
The number of active drug shortages has declined sharply since June, according to the FDA’s drug shortage database. Seventy-five drugs were in shortage as of Dec. 30, down from 194 in mid-June. The decline reflects updates to the FDA’s database,…
From payer shifts to regulatory milestones, GLP-1 therapies for obesity and diabetes continued to reshape the healthcare landscape in December. Here are six updates: